Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hui K. Gan"'
Publikováno v:
Molecules, Vol 25, Iss 20, p 4764 (2020)
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deli
Externí odkaz:
https://doaj.org/article/fd2c927ee8a84b3fa0e7808f9755a84a
Autor:
Andrea Mannucci, Adnan Nagrial, Catello Somma, Jason D. Lickliter, Jianjun Zou, Mark Voskoboynik, Michael Millward, Tarek Meniawy, Lianshan Zhang, Katherine Woods, Peter Grimison, Michael Lahn, Surein Arulananda, Hui K Gan, Pablo Fernandez-Penas, Andreas Behren, Bo Gao, Michelle Harrison, Howard Kallender, Stacey Luo
Publikováno v:
Drug Design, Development and Therapy. 14:1177-1189
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian
Autor:
Anne Poh Long, Anna K. Nowak, Samantha Bowyer, Weon Sup Lee, Lawrence Cher, Hui K Gan, Seon Young Lee, Michael Bynevelt, Jin-San Yoo, Graeme Jackson, George Iatropoulos
Publikováno v:
Neuro Oncol
The VEGF pathway remains an important target in GBM given its vascularity and autocrine VEGF signalling. Olinvacimab (TTAC-0001) is a fully humanised VEGFR2 Mab that binds and inhibits the receptor. This report assesses the safety, dosing schedules a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eac6579e97bf59e7121684c70dd0a86
https://europepmc.org/articles/PMC7650443/
https://europepmc.org/articles/PMC7650443/
Publikováno v:
Molecules, Vol 25, Iss 4764, p 4764 (2020)
Molecules
Molecules
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deli
Autor:
Jason D, Lickliter, Hui K, Gan, Mark, Voskoboynik, Surein, Arulananda, Bo, Gao, Adnan, Nagrial, Peter, Grimison, Michelle, Harrison, Jianjun, Zou, Lianshan, Zhang, Stacey, Luo, Michael, Lahn, Howard, Kallender, Andrea, Mannucci, Catello, Somma, Katherine, Woods, Andreas, Behren, Pablo, Fernandez-Penas, Michael, Millward, Tarek, Meniawy
Publikováno v:
Drug Design, Development and Therapy
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian
Publikováno v:
Current Immunotherapeutic Strategies in Cancer ISBN: 9783030237646
Exploiting the unique specificity of monoclonal antibodies has revolutionized the treatment and diagnosis of haematological and solid organ malignancies; bringing benefit to millions of patients over the past decades. Recent achievements include conj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1af76df02d2130c26febc0e10c5737f
https://doi.org/10.1007/978-3-030-23765-3_1
https://doi.org/10.1007/978-3-030-23765-3_1
Autor:
Ingrid Burvenich, Yit Wooi Goh, Sagun Parakh, Hui K Gan, Masakatsu Kotsuma, Andrew M. Scott, Zhanqi Liu, Fook-Thean Lee, Giorgio Senaldi, Graeme O'Keefe, Nancy Guo, Henri Tochon-Danguy, Angela Rigopoulos, Kenji Hirotani, Fiona Scott, Sylvia J. Gong
Publikováno v:
Theranostics
B7-H3 is a transmembrane protein widely expressed in a variety of cancers and has been shown to play a role in anti-tumor immunity. This study aims to develop a molecular imaging probe to identify B7-H3 expression in tumors and to develop 89Zr-DS-557
Autor:
Catherine E. Ellis, Michael Chisamore, Eric Angevin, Marc S. Ballas, Erminia Massarelli, Debra Rogan, Victor Moreno, Hui K Gan, Axel Hoos, Maria Vieito, Antoine Italiano, Riccardo Danielli, Arjun Vasant Balar, Courtney Henry, Frans L. Opdam, Xiao Ji, Francesco Ricci
Publikováno v:
Journal of Clinical Oncology. 39:4519-4519
4519 Background: INDUCE-1 is a first-in-human trial evaluating fela, an IgG4 ICOS agonist non-T-cell depleting mAb, as monotherapy (mono) and in combo with P. ECs include tumor types, such as UC, with high ICOS expression and immunotherapy-favorable
Autor:
Adnan Nagrial, Xiaoping Jin, Anna Rachelle Mislang, Yu Xia, Jermaine Coward, Baiyong Li, Rasha Cosman, Hui K Gan, Kon Yew Kwek, Dennis Xia, Zhongmin Maxwell Wang
Publikováno v:
Journal of Clinical Oncology. 39:2630-2630
2630 Background: AK117 is a novel humanized IgG4 monoclonal antibody (mAb) targeting CD47, a macrophage immune checkpoint that allows tumor cells to evade immune destruction by phagocytic cells. CD47 is a target expressed in many cancers. However, th
Publikováno v:
Nature Reviews Clinical Oncology, 14(11), 695-707. Nature Publishing Group
Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetr